Vaidya Sane Ayurved Laboratories Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book

Published 5 Aug 2026 | Healthcare Equipment & Supplies | Market Cap: ₹202 Cr

Targeting over 12,000 to 13,000 new patients per month soon, up from 8,000-9,000 currently, indicating growth in patient footfall and sales. Revenue for next year (FY'26) is expected around Rs.

From Vaidya Sane Ayurved Laboratories Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Price

₹170

Market Cap

₹202 Cr

P/E Ratio

22.4

How does Vaidya Sane Ayurved Laboratories Ltd rank in Healthcare Equipment & Supplies?

Compare Vaidya Sane Ayurved Laboratories Ltd against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

📊 Revenue & Sales Performance

→Targeting over 12,000 to 13,000 new patients per month soon, up from 8,000-9,000 currently, indicating growth in patient footfall and sales.
→Planning to add 30 new clinics in FY'26 across multiple states (Gujarat, Madhya Pradesh, Karnataka, Maharashtra) to expand reach.
→Hospital bed capacity to increase with additional beds at Khopoli, Nagpur, and Gujarat hospitals, including scaling Vadodara hospital from 20 to 100 beds in 12-15 months.
→Expected revenue growth of around 20% year-on-year, with monthly revenues scaling from Rs.7 crore in April 2025.
→Enrollment ratio improving, leading to increased care plan sales despite a dip in new patient footfall last year.
→Plans to increase prices for care plans in coming months.
→Long-term vision to have 1,000 clinics and 1,000 hospital beds by 2030, focusing on tier 1 and 2 cities across India.

📈 Profitability & Margins

→Revenue for next year (FY'26) is expected around Rs. 110 to Rs. 120 crores.
→Monthly revenue run rate targeted to grow by about 20% year-on-year.
→Profit after tax (PAT) margin anticipated around 11% to 12%.
→Operating leverage expected to improve margins further, with cost control sustaining employee expenses around Rs. 18 crores.
→Expansion plans include 30+ new clinics across multiple states and increase in hospital beds, contributing to higher revenues.
→Enrollment ratio for care plans and new patient footfall expected to rise sharply, fueling revenue growth.
→Conservative margin guidance of 16% indicated, with upside possible as growth accelerates and brand investments start yielding returns.
→Overall, steady-state margins and profitability improvements are sustainable due to operational efficiencies and improved product mix.

🏗️ Capital Expenditure Plans

→Permission secured for construction of 100 additional beds at Khopoli hospital.
→Nagpur hospital approved for 50% expansion adding 20 to 40 beds within the year.
→Vadodara hospital plans to expand from 30 to about 90-100 beds.
→Total targeted bed addition for FY'26 is approximately 200 beds.
→New clinic expansion planned with 30 additional clinics across Gujarat, Madhya Pradesh, Karnataka, and Maharashtra.
→Aggressive hospital network expansion including plans for over 1,000 beds and clinics by 2030, focusing on tier 1 and 2 cities in India.
→Institute of Preventive Cardiology aims to train over 10,000 physicians to support growth.
→Investment in marketing with onboarding of brand ambassador Sonu Sood and associated advertising content (intangible assets increased).
→Continued focus on asset-light franchise model to scale and maintain profitability.

💰 Fundraising & Capital Structure

The transcript on page 16 does not explicitly mention any current or future fundraising plans through debt or equity. However, related information includes: - Plans to expand clinics and hospitals aggressively, targeting 30 new clinics and adding about 200 beds in FY'26. - Strategic focus on scaling operations and improving revenue streams, which may imply potential future financing needs. - No direct references to ongoing or planned fundraises via debt or equity in the provided content. - Mentions of internal changes and cost optimizations suggest reliance on operational cash flow for growth currently. In summary, there is no explicit mention of new fundraising through debt or equity at this time in the transcript.

📋 Order Book & Pipeline

→The transcript does not explicitly mention the current or expected order book or pending orders.
→However, strategic focus is on expanding clinic network and hospital infrastructure, aiming for about 1,000 clinics and 1,000+ beds by 2030.
→New patient footfall targets are increasing from 9,000 to 12,000-13,000 per month, indicating growing demand.
→Planned addition of approximately 30 new clinics in FY'26.
→Hospital bed expansion plans: 100 more beds in Khopoli, 20-40 beds in Nagpur, and 60-70 beds in Vadodara expected within fiscal year 2026.
→Insurance tie-ups and corporate partnerships are being strengthened to boost hospital occupancy and revenue streams.
→Overall, the company is geared for growth with scaling operations and increasing patient enrollments, which suggests a robust and growing order pipeline.

Key Metrics

Frequently Asked Questions

What were Vaidya Sane Ayurved Laboratories Ltd Q4 FY25 results?

Targeting over 12,000 to 13,000 new patients per month soon, up from 8,000-9,000 currently, indicating growth in patient footfall and sales. Revenue for next year (FY'26) is expected around Rs.

What is Vaidya Sane Ayurved Laboratories Ltd share price analysis?

Vaidya Sane Ayurved Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 22.4 with a market cap of ₹202 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vaidya Sane Ayurved Laboratories Ltd planning capital expenditure?

Permission secured for construction of 100 additional beds at Khopoli hospital.

Keep Vaidya Sane Ayurved Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.